Evidence map›Paper›PMID 35092343›Full record

ArticleJournal of thrombosis and haemostasis : JTH2022

Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study.

Maria Teresa Pagliari, Frits R Rosendaal, Minoo Ahmadinejad, Zahra Badiee, Mohammad-Reza Baghaipour, Luciano Baronciani, Olga Benítez Hidalgo, Imre Bodó, Ulrich Budde, Giancarlo Castaman and 22 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 10 countries.

Maria Teresa PagliariFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.ORCID 0000-0003-0778-2271
Frits R RosendaalDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
Minoo AhmadinejadBlood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Zahra BadieeHemophilia-Thalassemia Center, Mashhad University of Medical Science, Mashad, Iran.
Mohammad-Reza BaghaipourIranian Hemophilia Comprehensive Treatment Centre, Tehran, Iran.
Luciano BaroncianiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Olga Benítez HidalgoHemophilia Unit,Hematology Department, Hospital Universitari Vall d'Hebron, Spain.
Imre BodóDepartment of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.ORCID 0000-0003-4170-8577
Ulrich BuddeHemostaseology Medilys Laborgesellschaft mbH, Hamburg, Germany.
Giancarlo CastamanCenter for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy.ORCID 0000-0003-4973-1317
Peyman EshghiPediatric Congenital Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Jenny GoudemandDepartment of Hematology and Transfusion, CHU Lille, University of Lille, Lille, France.
Mehran KarimiHematology Research Center,Nemazee Hospital, Shiraz University of Medical Science, Shiraz, Iran.ORCID 0000-0001-8555-1001
Bijan KeikhaeiThalassemia and Hemoglobinopathy Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Riitta LassilaResearch Program Unit in Oncology, University of Helsinki, Helsinki University Central Hospital, Coagulation Disorders, Helsinki, Finland.
Frank W G LeebeekDepartment of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands.
Maria Fernanda Lopez FernandezComplejo Hospitalario Universitario de A Coruña-Servicio de Hematología y Hemoterapia, A Coruña, Spain.
Pier Mannuccio MannucciFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
Renato MarinoHemophilia and Thrombosis Centre, University Hospital Policlinico, Bari, Italy.
Johannes OldenburgInstitute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany.
Ian PeakeFaculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom.
Cristina SantoroHematology, Hemophilia and Thrombosis Center, University Hospital Policlinico Umberto I, Rome, Italy.
Reinhard SchneppenheimDepartment of Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.
Andreas TiedeDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-3600-8536
Gholamreza ToogehThrombosis Hemostasis Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Alberto TosettoHemophilia and Thrombosis Center, Hematology Department, San Bortolo Hospital, Vicenza, Italy.ORCID 0000-0002-0119-5204
Marc TrossaertCentre Régional de Traitement de l'Hémophilie-Laboratoire d'Hématologie, Nantes, France.
Hamideh YadegariInstitute of Experimental Haematology and Transfusion Medicine, University of Bonn, Bonn, Germany.
Eva M K ZetterbergSkane University Hospital, Malmo, Sweden.
Flora PeyvandiFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.ORCID 0000-0001-7423-9864
Augusto B FedericiDepartment of Oncology and Oncohematology, Hematology and Transfusion Medicine, L. Sacco University Hospital, University of Milan, Milan, Italy.
Jeroen EikenboomDivision of Thrombosis and Hemostasis, Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0002-3268-5759
University of Milan · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITLeiden University Medical Center · NLUniversity of Bonn · DEAhvaz Jundishapur University of Medical Sciences · IRAzienda Ospedaliero-Universitaria Careggi · ITAzienda Universitaria Ospedaliera Consorziale - Policlinico Bari · ITCentre Hospitalier Universitaire de Nantes · FRComplexo Hospitalario Universitario A Coruña · ESErasmus MC · NLHemophilia Center of Iran · IRHigh Institute for Education and Research in Transfusion Medicine · IRMashhad University of Medical Sciences · IRMedizinische Hochschule Hannover · DEOspedale San Bortolo · ITPoliclinico Umberto I · ITSemmelweis University · HUShahid Beheshti University of Medical Sciences · IRShiraz University · IRSkåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundType 3 von Willebrand disease (VWD) is a severe bleeding disorder caused by the virtually complete absence of von Willebrand factor (VWF). Pathophysiological mechanisms of VWD like defective synthesis, secretion, and clearance of VWF have previously been evaluated using ratios of VWF propeptide (VWFpp) over VWF antigen (VWF:Ag) and factor (F)VIII coagulant activity (FVIII:C) over VWF:Ag.

objectiveTo investigate whether the VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios may also be applied to understand the pathophysiological mechanism underlying type 3 VWD and whether VWFpp is associated with bleeding severity.

methodsEuropean and Iranian type 3 patients were enrolled in the 3WINTERS-IPS study. Plasma samples and buffy coats were collected and a bleeding assessment tool was administered at enrolment. VWF:Ag, VWFpp, FVIII:C, and genetic analyses were performed centrally, to confirm patients' diagnoses. VWFpp/VWF:Ag and FVIII:C/VWF:Ag ratios were compared among different variant classes using the Mann-Whitney test. Median differences with 95% confidence intervals (CI) were estimated using the Hodges-Lehmann method. VWFpp association with bleeding symptoms was assessed using Spearman's rank correlation.

resultsHomozygosity/compound heterozygosity for missense variants showed higher VWFpp level and VWFpp/VWF:Ag ratio than homozygosity/compound heterozygosity for null variants ([VWFpp median difference, 1.4 IU/dl; 95% CI, 0.2-2.7; P = .016]; [VWFpp/VWF:Ag median difference, 1.4; 95% CI, 0-4.2; P = .054]). FVIII: C/VWF:Ag ratio was similarly increased in both. VWFpp level did not correlate with the bleeding symptoms (r = .024; P = .778).

conclusionsAn increased VWFpp/VWF:Ag ratio is indicative of missense variants, whereas FVIII:C/VWF:Ag ratio does not discriminate missense from null alleles. The VWFpp level was not associated with the severity of bleeding phenotype.

Indexed as

von Willebrand Diseasesvon Willebrand Disease, Type 3Factor VIIIHemorrhageHumansIranvon Willebrand FactorFactor VIIIvon Willebrand Factorbleedingmutationpropeptidevon Willebrand diseasevon Willebrand factor

Identifiers

PMID35092343
PMCPMC9305521
OpenAlexW4210693078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.